NOVEL Health Strategies team is presenting 10 studies at ISPOR Annual Meeting in Philadelphia, PA on market access strategy, pricing and health economic and outcomes research trends.

One of NOVEL's presentations was also selected for PODIUM PRESENTATION.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

In-person replays of all presentations are available upon request

PHP 167: TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL GUIDELINES

PSS 32: PATIENT REPORTED OUTCOMES IN GLAUCOMA A SYSTEMATIC REVIEW

PCN 53: SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF PANCREATIC CANCER

PCN 54: SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF CUTANEOUS T-CELL LYMPHOMA

PHP 109: OVERVIEW AND IMPORTANCE OF NUB PROCESS FOR MARKET ACCESS OF IN-PATIENT DRUGS AND DEVICES IN GERMANY

PHP 14: IMPACT OF 2014 ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MANAGED CARE

PHP 105: IMPACT OF NEW CHANGES DUE TO AFFORDABLE CARE ACT ON US MARKET ACCESS

PHP 101: COMPARATIVE EFFECTIVENESS, APPROVAL RATES AND PRICING OF DRUGS WITH FDA'S BREAKTHROUGH THERAPY DESIGNATIONS

PSY 75: COMPARISON OF ULTRA ORPHAN AND CANCER DRUG PRICING IN THE US AND THE UK

HT 1: SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES: LESSONS LEARNED FROM PUBLISHED HTAS AND STUDIES (Podium Presentation) PDF is available on ISPOR website